Analyst Notes: Multiple Myeloma - What more should Medical Affairs be doing?

The latest FirstView Medical Affairs Reputations reports assess the performance of multiple myeloma medical affairs teams and delves into their reputation amongst physicians in the US and the EU5 countries (France, Germany, Italy, Spain and the UK). Which drugs are benefiting from the most active and supportive teams? What interactions are hitting home with physicians and prompting high satisfaction scores? What activities are valued the most and least? Ultimately, who is providing the best medical affairs services in the myeloma market?

Medical oncologists and haematologists currently prescribing treatments for multiple myeloma drugs were surveyed to assess the reputation and performance of the medical affairs teams supporting 7 leading drugs: Darzalex, Farydak, Kyprolis, Imnovid/Pomalyst, Revlimid; Thalidomide/Thalomid and Velcade. Empliciti and Ninlaro are also included in the US report. The results are revealed in Medical Affairs Reputations: Multiple Myeloma (2017).

Find out how each team fares against the rest, see who the star performers are and who has more to do. Choose either the US or EU5 report for a unique insight into the minds of multiple myeloma drug prescribers in your preferred market.

Physician needs and priorities?

An at-a-glance view of the 'need-gap analysis' for each drug highlights the activities physicians value the most and where they are happy with the support they are getting, as well as the key areas where satisfaction could be improved. Activities are categorised into primary and secondary importance to further aid interpretation of the results.

How to interact – and how often?

Find out if US survey respondents differ from their EU5 counterparts when it comes to the level of support required from medical affairs professionals. Do physicians prefer a combination of medical meetings, education events and one-to-ones, or are they embracing digital channels?

The physicians' wish list?

For US and European respondents, you'll be able to find out what the most valued attributes are when it comes to the support they need from medical affairs teams. Speed, accuracy, information on competitive products, support with grant applications and several other attributes are tested.

Pitching each team against the rest        

A key feature of the Medical Affairs Reputations report format is the EdgeMap. This offers a visual representation of competitive performance of each medical affairs team against each other, broken down by specific attributes. See instantly who leads and who lags for the core medical affairs activities including speed of response, provision of suitable resources, proof of clinical value and thought leadership opportunities – as well as other key factors.

Full Survey Results Now Available

All this and more, including the full survey results from either the US or EU5 can be ordered online today. Why pay more? These revealing reports provide a robust assessment of your current medical affairs team performance without the need to commission and then await the results from expensive bespoke research.

Medical Affairs Reputations: Multiple Myeloma (2017) is available now.

Purchase and download at the FirstView reports store.

Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.